Yuet-Kin Leung
Concepts (463)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Estrogen Receptor beta | 17 | 2019 | 54 | 3.190 |
Why?
| | Endocrine Disruptors | 7 | 2025 | 34 | 2.500 |
Why?
| | Prostatic Neoplasms | 15 | 2022 | 401 | 2.420 |
Why?
| | Phenols | 10 | 2025 | 94 | 1.890 |
Why?
| | Epigenesis, Genetic | 11 | 2025 | 412 | 1.880 |
Why?
| | Benzhydryl Compounds | 9 | 2021 | 70 | 1.850 |
Why?
| | Environmental Pollutants | 4 | 2024 | 110 | 1.450 |
Why?
| | DNA Methylation | 13 | 2025 | 592 | 1.250 |
Why?
| | Gene Expression Regulation, Neoplastic | 9 | 2024 | 868 | 1.140 |
Why?
| | Estrogens | 7 | 2020 | 224 | 1.130 |
Why?
| | Cell Line, Tumor | 21 | 2024 | 1470 | 0.950 |
Why?
| | Estradiol | 9 | 2021 | 215 | 0.900 |
Why?
| | Signal Transduction | 12 | 2021 | 1748 | 0.890 |
Why?
| | Carcinoma, Hepatocellular | 2 | 2024 | 213 | 0.840 |
Why?
| | Breast Neoplasms | 7 | 2016 | 1223 | 0.820 |
Why?
| | beta Catenin | 1 | 2024 | 107 | 0.790 |
Why?
| | Cell Movement | 4 | 2020 | 279 | 0.790 |
Why?
| | Endocrine System | 1 | 2023 | 16 | 0.780 |
Why?
| | Wnt Signaling Pathway | 1 | 2024 | 98 | 0.780 |
Why?
| | Receptors, Androgen | 2 | 2022 | 48 | 0.760 |
Why?
| | Mice, Knockout | 3 | 2026 | 910 | 0.760 |
Why?
| | Liver Neoplasms | 2 | 2024 | 347 | 0.740 |
Why?
| | Occupational Exposure | 3 | 2021 | 106 | 0.720 |
Why?
| | Antineoplastic Agents | 5 | 2021 | 1232 | 0.710 |
Why?
| | Cell Proliferation | 10 | 2022 | 1031 | 0.700 |
Why?
| | Environmental Exposure | 7 | 2024 | 222 | 0.660 |
Why?
| | Protein Kinase Inhibitors | 5 | 2023 | 234 | 0.650 |
Why?
| | Toxicity Tests | 1 | 2020 | 57 | 0.640 |
Why?
| | Humans | 64 | 2025 | 53246 | 0.610 |
Why?
| | Animals | 27 | 2026 | 13528 | 0.590 |
Why?
| | Mammary Neoplasms, Experimental | 2 | 2017 | 122 | 0.580 |
Why?
| | Chromosomes, Human, X | 1 | 2018 | 18 | 0.550 |
Why?
| | Leukemia, Myeloid, Acute | 3 | 2023 | 208 | 0.500 |
Why?
| | Protective Clothing | 1 | 2015 | 6 | 0.470 |
Why?
| | Firefighters | 1 | 2015 | 3 | 0.470 |
Why?
| | Estrogen Antagonists | 1 | 2015 | 21 | 0.460 |
Why?
| | Antineoplastic Agents, Hormonal | 2 | 2014 | 56 | 0.460 |
Why?
| | Transcriptional Activation | 4 | 2013 | 128 | 0.440 |
Why?
| | Response Elements | 2 | 2013 | 29 | 0.430 |
Why?
| | Apoptosis | 5 | 2026 | 1139 | 0.420 |
Why?
| | MicroRNAs | 3 | 2016 | 397 | 0.420 |
Why?
| | CpG Islands | 8 | 2025 | 114 | 0.410 |
Why?
| | Female | 34 | 2025 | 28792 | 0.410 |
Why?
| | Prostate | 6 | 2016 | 118 | 0.410 |
Why?
| | Fetal Blood | 3 | 2025 | 79 | 0.400 |
Why?
| | Promoter Regions, Genetic | 4 | 2019 | 465 | 0.390 |
Why?
| | Sp1 Transcription Factor | 2 | 2024 | 20 | 0.390 |
Why?
| | Exons | 1 | 2013 | 100 | 0.380 |
Why?
| | Rats | 11 | 2021 | 3164 | 0.380 |
Why?
| | Male | 34 | 2024 | 27444 | 0.380 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2013 | 128 | 0.370 |
Why?
| | Prenatal Exposure Delayed Effects | 4 | 2021 | 214 | 0.370 |
Why?
| | Diet, High-Fat | 4 | 2021 | 243 | 0.350 |
Why?
| | Maternal Exposure | 3 | 2025 | 103 | 0.330 |
Why?
| | Proto-Oncogene Proteins c-ret | 2 | 2022 | 33 | 0.330 |
Why?
| | Muscle Proteins | 1 | 2013 | 350 | 0.320 |
Why?
| | Placenta | 2 | 2025 | 146 | 0.320 |
Why?
| | Tumor Suppressor Protein p53 | 2 | 2019 | 228 | 0.320 |
Why?
| | Receptors, Estrogen | 4 | 2019 | 134 | 0.310 |
Why?
| | Pregnancy | 11 | 2025 | 2610 | 0.310 |
Why?
| | Adenocarcinoma | 2 | 2011 | 405 | 0.310 |
Why?
| | Pyrimidines | 2 | 2022 | 206 | 0.300 |
Why?
| | Spermatogenesis | 2 | 2021 | 16 | 0.300 |
Why?
| | RNA, Messenger | 5 | 2022 | 1133 | 0.290 |
Why?
| | HEK293 Cells | 5 | 2021 | 235 | 0.280 |
Why?
| | Air Pollutants, Occupational | 2 | 2020 | 14 | 0.280 |
Why?
| | Dose-Response Relationship, Drug | 6 | 2021 | 1367 | 0.280 |
Why?
| | Orphan Nuclear Receptors | 2 | 2019 | 14 | 0.280 |
Why?
| | Mice | 7 | 2026 | 5982 | 0.280 |
Why?
| | fms-Like Tyrosine Kinase 3 | 3 | 2023 | 20 | 0.270 |
Why?
| | Transcription, Genetic | 4 | 2013 | 374 | 0.270 |
Why?
| | Mass Spectrometry | 2 | 2024 | 294 | 0.260 |
Why?
| | Mutation | 5 | 2023 | 1338 | 0.260 |
Why?
| | Epigenomics | 2 | 2019 | 76 | 0.260 |
Why?
| | Protein Isoforms | 4 | 2013 | 124 | 0.250 |
Why?
| | Metabolome | 2 | 2025 | 109 | 0.250 |
Why?
| | Gene Expression Profiling | 5 | 2015 | 1112 | 0.240 |
Why?
| | Phosphorylation | 5 | 2021 | 533 | 0.240 |
Why?
| | Histone Deacetylases | 1 | 2026 | 59 | 0.230 |
Why?
| | Retina | 1 | 2026 | 76 | 0.220 |
Why?
| | Cytochrome P-450 CYP1A1 | 1 | 2005 | 26 | 0.220 |
Why?
| | Lung Neoplasms | 3 | 2022 | 645 | 0.220 |
Why?
| | Reperfusion Injury | 1 | 2026 | 83 | 0.220 |
Why?
| | Androgens | 2 | 2022 | 70 | 0.220 |
Why?
| | Protein Processing, Post-Translational | 3 | 2012 | 149 | 0.220 |
Why?
| | Veterans | 2 | 2021 | 580 | 0.220 |
Why?
| | Chironomidae | 1 | 2004 | 1 | 0.210 |
Why?
| | Ferrochelatase | 1 | 2004 | 1 | 0.210 |
Why?
| | Aqueous Humor | 1 | 2024 | 10 | 0.210 |
Why?
| | Retinal Artery Occlusion | 1 | 2024 | 11 | 0.210 |
Why?
| | NF-kappa B | 1 | 2006 | 327 | 0.210 |
Why?
| | Structure-Activity Relationship | 5 | 2022 | 396 | 0.210 |
Why?
| | Nanoparticles | 2 | 2016 | 133 | 0.210 |
Why?
| | Butter | 2 | 2021 | 4 | 0.210 |
Why?
| | Proteome | 1 | 2006 | 178 | 0.210 |
Why?
| | Copper | 1 | 2004 | 47 | 0.210 |
Why?
| | Pyridines | 2 | 2023 | 135 | 0.200 |
Why?
| | Glycyrrhiza | 1 | 2003 | 3 | 0.200 |
Why?
| | Drug Discovery | 2 | 2021 | 94 | 0.200 |
Why?
| | Wounds and Injuries | 2 | 2018 | 301 | 0.200 |
Why?
| | Proteins | 2 | 2006 | 351 | 0.200 |
Why?
| | Disease Models, Animal | 3 | 2024 | 1517 | 0.200 |
Why?
| | Proto-Oncogene Proteins c-fos | 1 | 2003 | 60 | 0.200 |
Why?
| | Binding Sites | 2 | 2022 | 373 | 0.200 |
Why?
| | Hormones | 1 | 2023 | 58 | 0.190 |
Why?
| | Antineoplastic Agents, Phytogenic | 3 | 2016 | 71 | 0.190 |
Why?
| | Tumor Suppressor Proteins | 2 | 2020 | 130 | 0.190 |
Why?
| | Neoplasm Invasiveness | 2 | 2014 | 281 | 0.180 |
Why?
| | Methylcholanthrene | 1 | 2002 | 10 | 0.180 |
Why?
| | Sp3 Transcription Factor | 1 | 2022 | 5 | 0.180 |
Why?
| | RNA Polymerase II | 1 | 2022 | 15 | 0.180 |
Why?
| | Infertility, Male | 1 | 2021 | 12 | 0.170 |
Why?
| | Proteomics | 1 | 2024 | 337 | 0.170 |
Why?
| | Aminoquinolines | 1 | 2021 | 8 | 0.170 |
Why?
| | Phthalazines | 1 | 2021 | 20 | 0.170 |
Why?
| | Disease Susceptibility | 2 | 2012 | 96 | 0.170 |
Why?
| | Forkhead Transcription Factors | 2 | 2012 | 120 | 0.170 |
Why?
| | Thiophenes | 1 | 2021 | 45 | 0.170 |
Why?
| | Computational Biology | 3 | 2019 | 209 | 0.170 |
Why?
| | Plant Extracts | 1 | 2003 | 200 | 0.170 |
Why?
| | Ovarian Neoplasms | 1 | 2005 | 459 | 0.170 |
Why?
| | Glucuronosyltransferase | 1 | 2002 | 121 | 0.170 |
Why?
| | Risk | 3 | 2017 | 306 | 0.170 |
Why?
| | Dietary Fats | 1 | 2021 | 133 | 0.160 |
Why?
| | Infant, Newborn | 4 | 2025 | 2913 | 0.160 |
Why?
| | Adult | 11 | 2025 | 14541 | 0.160 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2021 | 136 | 0.160 |
Why?
| | Transforming Growth Factor beta | 1 | 2021 | 136 | 0.160 |
Why?
| | Estrogen Receptor alpha | 3 | 2019 | 85 | 0.160 |
Why?
| | DNA Modification Methylases | 1 | 2020 | 29 | 0.160 |
Why?
| | Sleep Initiation and Maintenance Disorders | 1 | 2020 | 42 | 0.160 |
Why?
| | Isocitrate Dehydrogenase | 1 | 2020 | 21 | 0.160 |
Why?
| | Molecular Sequence Data | 4 | 2006 | 759 | 0.160 |
Why?
| | DNA Repair Enzymes | 1 | 2020 | 44 | 0.160 |
Why?
| | Pyruvate Kinase | 1 | 2020 | 7 | 0.160 |
Why?
| | Pyrroles | 1 | 2020 | 74 | 0.160 |
Why?
| | Hair | 2 | 2018 | 29 | 0.150 |
Why?
| | Up-Regulation | 3 | 2019 | 456 | 0.150 |
Why?
| | Drug Design | 1 | 2020 | 121 | 0.150 |
Why?
| | Sequence Analysis, RNA | 1 | 2020 | 97 | 0.150 |
Why?
| | Random Allocation | 2 | 2017 | 284 | 0.150 |
Why?
| | Pharyngeal Neoplasms | 1 | 2019 | 1 | 0.150 |
Why?
| | Endometrial Neoplasms | 1 | 2020 | 143 | 0.150 |
Why?
| | Mouth Neoplasms | 1 | 2019 | 22 | 0.150 |
Why?
| | Glioma | 1 | 2020 | 83 | 0.150 |
Why?
| | Collagen Type III | 1 | 2019 | 7 | 0.150 |
Why?
| | Subcellular Fractions | 2 | 2012 | 33 | 0.150 |
Why?
| | Cost of Illness | 2 | 2018 | 121 | 0.150 |
Why?
| | Amino Acid Sequence | 3 | 2006 | 563 | 0.140 |
Why?
| | Liver Failure, Acute | 1 | 2019 | 57 | 0.140 |
Why?
| | Military Personnel | 1 | 2020 | 173 | 0.140 |
Why?
| | Tissue Array Analysis | 3 | 2016 | 45 | 0.140 |
Why?
| | Collagen Type I | 1 | 2019 | 83 | 0.140 |
Why?
| | Methylmercury Compounds | 1 | 2018 | 4 | 0.140 |
Why?
| | Denmark | 1 | 2018 | 23 | 0.140 |
Why?
| | Stress, Psychological | 1 | 2020 | 283 | 0.140 |
Why?
| | Mortality, Premature | 1 | 2018 | 12 | 0.140 |
Why?
| | Depressive Disorder | 1 | 2020 | 336 | 0.140 |
Why?
| | Polychlorinated Biphenyls | 1 | 2018 | 36 | 0.130 |
Why?
| | Pregnancy in Diabetics | 1 | 2018 | 24 | 0.130 |
Why?
| | Anxiety | 1 | 2020 | 321 | 0.130 |
Why?
| | Water Pollutants, Chemical | 1 | 2018 | 54 | 0.130 |
Why?
| | Receptors, Aryl Hydrocarbon | 1 | 2017 | 30 | 0.130 |
Why?
| | Urethane | 1 | 2017 | 5 | 0.130 |
Why?
| | Histone Demethylases | 1 | 2017 | 22 | 0.130 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 177 | 0.130 |
Why?
| | Neoplasms | 2 | 2005 | 1335 | 0.130 |
Why?
| | Morbidity | 1 | 2018 | 132 | 0.130 |
Why?
| | Cells, Cultured | 4 | 2019 | 1569 | 0.130 |
Why?
| | Coronavirus Infections | 1 | 2020 | 188 | 0.130 |
Why?
| | Protein Binding | 2 | 2011 | 670 | 0.130 |
Why?
| | Rats, Sprague-Dawley | 5 | 2021 | 1544 | 0.120 |
Why?
| | Gene Expression | 2 | 2018 | 618 | 0.120 |
Why?
| | Mammary Glands, Animal | 1 | 2017 | 68 | 0.120 |
Why?
| | Immunohistochemistry | 4 | 2016 | 975 | 0.120 |
Why?
| | Fibroblasts | 1 | 2019 | 363 | 0.120 |
Why?
| | Research Design | 1 | 2019 | 373 | 0.120 |
Why?
| | Sex Characteristics | 1 | 2018 | 204 | 0.120 |
Why?
| | Cholesterol | 1 | 2017 | 161 | 0.120 |
Why?
| | 5-Methylcytosine | 1 | 2016 | 16 | 0.120 |
Why?
| | Brain Neoplasms | 1 | 2020 | 319 | 0.120 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2019 | 332 | 0.120 |
Why?
| | Heart Diseases | 1 | 2019 | 221 | 0.120 |
Why?
| | Membrane Proteins | 2 | 2010 | 333 | 0.120 |
Why?
| | Environmental Health | 1 | 2016 | 14 | 0.120 |
Why?
| | Paclitaxel | 1 | 2016 | 91 | 0.120 |
Why?
| | Developed Countries | 1 | 2016 | 17 | 0.120 |
Why?
| | Reproduction | 1 | 2016 | 64 | 0.120 |
Why?
| | Risk Factors | 5 | 2020 | 4018 | 0.120 |
Why?
| | Sexual Maturation | 1 | 2015 | 19 | 0.120 |
Why?
| | Pandemics | 1 | 2020 | 595 | 0.120 |
Why?
| | Myocardium | 1 | 2019 | 471 | 0.120 |
Why?
| | Embryo Implantation | 1 | 2015 | 5 | 0.120 |
Why?
| | Embryonic Development | 1 | 2015 | 18 | 0.110 |
Why?
| | Image Interpretation, Computer-Assisted | 1 | 2016 | 99 | 0.110 |
Why?
| | Developing Countries | 1 | 2016 | 66 | 0.110 |
Why?
| | Interferons | 1 | 2015 | 39 | 0.110 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2016 | 58 | 0.110 |
Why?
| | RNA, Untranslated | 1 | 2015 | 15 | 0.110 |
Why?
| | Prostatectomy | 1 | 2016 | 84 | 0.110 |
Why?
| | Histone Code | 1 | 2015 | 32 | 0.110 |
Why?
| | Polyglycolic Acid | 1 | 2015 | 7 | 0.110 |
Why?
| | Histidine | 1 | 2015 | 15 | 0.110 |
Why?
| | Myeloid Cells | 1 | 2015 | 45 | 0.110 |
Why?
| | Chemistry, Pharmaceutical | 1 | 2015 | 35 | 0.110 |
Why?
| | Tumor Cells, Cultured | 3 | 2022 | 441 | 0.110 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2016 | 235 | 0.110 |
Why?
| | Particle Size | 1 | 2015 | 76 | 0.110 |
Why?
| | Middle Aged | 8 | 2024 | 13422 | 0.110 |
Why?
| | Aged | 7 | 2024 | 10430 | 0.110 |
Why?
| | Drug Carriers | 1 | 2015 | 68 | 0.110 |
Why?
| | Receptor, erbB-2 | 1 | 2015 | 79 | 0.110 |
Why?
| | Lysosomes | 1 | 2015 | 68 | 0.110 |
Why?
| | Inflammasomes | 1 | 2015 | 66 | 0.110 |
Why?
| | Polyethylene Glycols | 1 | 2015 | 95 | 0.110 |
Why?
| | Polycomb Repressive Complex 2 | 1 | 2014 | 48 | 0.110 |
Why?
| | Lactic Acid | 1 | 2015 | 78 | 0.110 |
Why?
| | HMGA Proteins | 1 | 2014 | 2 | 0.110 |
Why?
| | Base Sequence | 3 | 2005 | 620 | 0.100 |
Why?
| | Maternal Mortality | 1 | 2014 | 28 | 0.100 |
Why?
| | Isoenzymes | 2 | 2005 | 165 | 0.100 |
Why?
| | Malaria | 1 | 2014 | 37 | 0.100 |
Why?
| | Caspase 7 | 1 | 2013 | 7 | 0.100 |
Why?
| | Kaplan-Meier Estimate | 2 | 2017 | 487 | 0.100 |
Why?
| | Histones | 2 | 2015 | 318 | 0.100 |
Why?
| | MCF-7 Cells | 1 | 2013 | 65 | 0.100 |
Why?
| | Repressor Proteins | 1 | 2014 | 149 | 0.100 |
Why?
| | Tuberculosis | 1 | 2014 | 133 | 0.100 |
Why?
| | 5' Untranslated Regions | 1 | 2013 | 29 | 0.100 |
Why?
| | Histone Acetyltransferases | 1 | 2013 | 26 | 0.100 |
Why?
| | Open Reading Frames | 1 | 2013 | 52 | 0.100 |
Why?
| | Drug Delivery Systems | 1 | 2015 | 148 | 0.100 |
Why?
| | HIV Infections | 2 | 2014 | 402 | 0.100 |
Why?
| | DNA | 1 | 2016 | 535 | 0.100 |
Why?
| | Estrogens, Non-Steroidal | 2 | 2015 | 15 | 0.100 |
Why?
| | Vehicle Emissions | 1 | 2012 | 10 | 0.100 |
Why?
| | Models, Biological | 2 | 2017 | 737 | 0.090 |
Why?
| | Metabolomics | 2 | 2025 | 156 | 0.090 |
Why?
| | Genetic Predisposition to Disease | 1 | 2015 | 533 | 0.090 |
Why?
| | Transcriptome | 1 | 2015 | 368 | 0.090 |
Why?
| | Air Pollutants | 1 | 2012 | 75 | 0.090 |
Why?
| | RNA Splicing | 1 | 2012 | 43 | 0.090 |
Why?
| | Doxorubicin | 1 | 2013 | 248 | 0.090 |
Why?
| | Cisplatin | 1 | 2013 | 282 | 0.090 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2012 | 84 | 0.090 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2016 | 523 | 0.090 |
Why?
| | Mice, Inbred C57BL | 3 | 2026 | 1925 | 0.090 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2012 | 92 | 0.090 |
Why?
| | Antibodies | 1 | 2012 | 147 | 0.090 |
Why?
| | MAP Kinase Signaling System | 1 | 2012 | 127 | 0.090 |
Why?
| | Diet | 1 | 2015 | 611 | 0.080 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 3 | 2015 | 579 | 0.080 |
Why?
| | Protein Biosynthesis | 1 | 2013 | 268 | 0.080 |
Why?
| | Kruppel-Like Transcription Factors | 1 | 2011 | 36 | 0.080 |
Why?
| | Cell Cycle | 1 | 2012 | 237 | 0.080 |
Why?
| | Racemases and Epimerases | 1 | 2011 | 18 | 0.080 |
Why?
| | Cell Transformation, Neoplastic | 2 | 2017 | 187 | 0.080 |
Why?
| | Models, Genetic | 1 | 2011 | 169 | 0.080 |
Why?
| | Cell Nucleus | 2 | 2016 | 187 | 0.080 |
Why?
| | Molecular Structure | 2 | 2021 | 320 | 0.080 |
Why?
| | Gene Expression Regulation | 3 | 2015 | 1003 | 0.080 |
Why?
| | Introns | 1 | 2010 | 51 | 0.080 |
Why?
| | Carcinogens | 2 | 2015 | 194 | 0.080 |
Why?
| | Testosterone | 2 | 2016 | 142 | 0.080 |
Why?
| | Gene Silencing | 1 | 2010 | 122 | 0.080 |
Why?
| | Manganese Poisoning | 1 | 2009 | 5 | 0.080 |
Why?
| | Disease-Free Survival | 1 | 2010 | 466 | 0.070 |
Why?
| | Young Adult | 4 | 2025 | 4514 | 0.070 |
Why?
| | Proportional Hazards Models | 1 | 2010 | 445 | 0.070 |
Why?
| | Oligonucleotide Array Sequence Analysis | 3 | 2007 | 412 | 0.070 |
Why?
| | Asthma | 1 | 2012 | 319 | 0.070 |
Why?
| | Methylation | 2 | 2020 | 127 | 0.070 |
Why?
| | Community-Based Participatory Research | 1 | 2009 | 203 | 0.070 |
Why?
| | Enzyme Activation | 2 | 2006 | 267 | 0.070 |
Why?
| | Sequence Analysis, DNA | 2 | 2019 | 216 | 0.060 |
Why?
| | Quality-Adjusted Life Years | 2 | 2018 | 67 | 0.060 |
Why?
| | Apigenin | 1 | 2006 | 7 | 0.060 |
Why?
| | Estrogen Receptor Modulators | 1 | 2006 | 5 | 0.060 |
Why?
| | Presenilin-2 | 1 | 2006 | 2 | 0.060 |
Why?
| | Yeasts | 1 | 2006 | 8 | 0.060 |
Why?
| | Sequence Analysis, Protein | 1 | 2006 | 19 | 0.060 |
Why?
| | Dimerization | 1 | 2006 | 50 | 0.060 |
Why?
| | Growth Differentiation Factor 1 | 1 | 2006 | 2 | 0.060 |
Why?
| | Interleukin-12 | 1 | 2006 | 26 | 0.060 |
Why?
| | Phagocytosis | 1 | 2026 | 59 | 0.060 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2006 | 52 | 0.060 |
Why?
| | Cohort Studies | 1 | 2010 | 1557 | 0.060 |
Why?
| | Sex Factors | 2 | 2019 | 747 | 0.060 |
Why?
| | Mortality | 2 | 2018 | 98 | 0.060 |
Why?
| | Interleukin-8 | 1 | 2006 | 85 | 0.060 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2006 | 107 | 0.060 |
Why?
| | Benzo(a)pyrene | 1 | 2005 | 13 | 0.060 |
Why?
| | Models, Molecular | 1 | 2006 | 352 | 0.060 |
Why?
| | Epithelium | 1 | 2005 | 64 | 0.060 |
Why?
| | Phthalic Acids | 1 | 2025 | 7 | 0.060 |
Why?
| | Molecular Conformation | 1 | 2005 | 66 | 0.050 |
Why?
| | Genes, p53 | 1 | 2005 | 51 | 0.050 |
Why?
| | Genes, Tumor Suppressor | 1 | 2005 | 73 | 0.050 |
Why?
| | Alternative Splicing | 1 | 2005 | 61 | 0.050 |
Why?
| | Ovary | 1 | 2005 | 103 | 0.050 |
Why?
| | Leukocytes, Mononuclear | 1 | 2025 | 122 | 0.050 |
Why?
| | Phosphopyruvate Hydratase | 1 | 2024 | 10 | 0.050 |
Why?
| | Cations, Divalent | 1 | 2004 | 6 | 0.050 |
Why?
| | Vitreous Body | 1 | 2024 | 19 | 0.050 |
Why?
| | Iron-Sulfur Proteins | 1 | 2004 | 9 | 0.050 |
Why?
| | Paracentesis | 1 | 2024 | 13 | 0.050 |
Why?
| | Transfection | 1 | 2005 | 359 | 0.050 |
Why?
| | Eye Proteins | 1 | 2024 | 17 | 0.050 |
Why?
| | Survival Analysis | 2 | 2016 | 659 | 0.050 |
Why?
| | Organizational Objectives | 2 | 2014 | 35 | 0.050 |
Why?
| | Metals | 1 | 2004 | 37 | 0.050 |
Why?
| | Sequence Alignment | 1 | 2004 | 119 | 0.050 |
Why?
| | Cloning, Molecular | 1 | 2004 | 175 | 0.050 |
Why?
| | Age Distribution | 2 | 2014 | 175 | 0.050 |
Why?
| | Cell Survival | 2 | 2021 | 600 | 0.050 |
Why?
| | Receptors, Urokinase Plasminogen Activator | 1 | 2003 | 2 | 0.050 |
Why?
| | Plasminogen Activator Inhibitor 1 | 1 | 2003 | 7 | 0.050 |
Why?
| | NAD(P)H Dehydrogenase (Quinone) | 1 | 2003 | 11 | 0.050 |
Why?
| | Glutathione S-Transferase pi | 1 | 2003 | 25 | 0.050 |
Why?
| | Deoxyguanosine | 1 | 2003 | 27 | 0.050 |
Why?
| | Blotting, Northern | 1 | 2003 | 106 | 0.050 |
Why?
| | Clone Cells | 1 | 2003 | 76 | 0.050 |
Why?
| | Vitrectomy | 1 | 2024 | 61 | 0.050 |
Why?
| | Transcription Factor AP-1 | 1 | 2003 | 62 | 0.050 |
Why?
| | Pilot Projects | 2 | 2020 | 727 | 0.050 |
Why?
| | Molecular Docking Simulation | 1 | 2023 | 93 | 0.050 |
Why?
| | Macrophages | 1 | 2026 | 380 | 0.050 |
Why?
| | Receptors, Cell Surface | 1 | 2003 | 109 | 0.050 |
Why?
| | Glutathione Transferase | 1 | 2003 | 174 | 0.050 |
Why?
| | Kinetics | 1 | 2004 | 607 | 0.050 |
Why?
| | Herbal Medicine | 1 | 2002 | 3 | 0.050 |
Why?
| | Dactinomycin | 1 | 2002 | 24 | 0.040 |
Why?
| | Nucleic Acid Synthesis Inhibitors | 1 | 2002 | 15 | 0.040 |
Why?
| | RNA Stability | 1 | 2002 | 29 | 0.040 |
Why?
| | Inheritance Patterns | 1 | 2021 | 22 | 0.040 |
Why?
| | Prognosis | 2 | 2017 | 2118 | 0.040 |
Why?
| | Smad Proteins | 1 | 2021 | 16 | 0.040 |
Why?
| | Incineration | 1 | 2021 | 5 | 0.040 |
Why?
| | Receptors, Transforming Growth Factor beta | 1 | 2021 | 29 | 0.040 |
Why?
| | Amino Acids | 1 | 2023 | 382 | 0.040 |
Why?
| | Testis | 1 | 2021 | 74 | 0.040 |
Why?
| | Drug Screening Assays, Antitumor | 1 | 2021 | 136 | 0.040 |
Why?
| | Staining and Labeling | 2 | 2016 | 94 | 0.040 |
Why?
| | Mitochondria | 1 | 2005 | 447 | 0.040 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2021 | 142 | 0.040 |
Why?
| | Small Molecule Libraries | 1 | 2021 | 66 | 0.040 |
Why?
| | Phytoestrogens | 2 | 2014 | 23 | 0.040 |
Why?
| | Maternal Nutritional Physiological Phenomena | 1 | 2021 | 64 | 0.040 |
Why?
| | Hypesthesia | 1 | 2020 | 16 | 0.040 |
Why?
| | Loneliness | 1 | 2020 | 16 | 0.040 |
Why?
| | Chemistry Techniques, Synthetic | 1 | 2020 | 21 | 0.040 |
Why?
| | Memory Disorders | 1 | 2020 | 47 | 0.040 |
Why?
| | Alcohol Oxidoreductases | 1 | 2020 | 13 | 0.040 |
Why?
| | Lymphangioleiomyomatosis | 1 | 2020 | 4 | 0.040 |
Why?
| | Wound Healing | 1 | 2022 | 226 | 0.040 |
Why?
| | Child, Preschool | 3 | 2016 | 4164 | 0.040 |
Why?
| | Fear | 1 | 2020 | 85 | 0.040 |
Why?
| | Hep G2 Cells | 1 | 2019 | 38 | 0.040 |
Why?
| | Oxidative Stress | 1 | 2003 | 820 | 0.040 |
Why?
| | Adaptation, Psychological | 1 | 2020 | 233 | 0.040 |
Why?
| | Acetylcysteine | 1 | 2019 | 104 | 0.040 |
Why?
| | Rats, Wistar | 1 | 2019 | 192 | 0.030 |
Why?
| | Cross-Sectional Studies | 1 | 2023 | 1723 | 0.030 |
Why?
| | Adolescent | 3 | 2016 | 6912 | 0.030 |
Why?
| | Linear Models | 1 | 2019 | 287 | 0.030 |
Why?
| | Biopsy | 1 | 2020 | 600 | 0.030 |
Why?
| | Fibrosis | 1 | 2019 | 198 | 0.030 |
Why?
| | Aging | 1 | 2003 | 715 | 0.030 |
Why?
| | Diet, Atherogenic | 1 | 2017 | 10 | 0.030 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 2017 | 39 | 0.030 |
Why?
| | Injections, Intraperitoneal | 1 | 2017 | 55 | 0.030 |
Why?
| | Calcium Phosphates | 1 | 2016 | 5 | 0.030 |
Why?
| | Gene Regulatory Networks | 1 | 2017 | 112 | 0.030 |
Why?
| | Child | 3 | 2016 | 7384 | 0.030 |
Why?
| | Lung | 1 | 2020 | 481 | 0.030 |
Why?
| | Acetaminophen | 1 | 2019 | 277 | 0.030 |
Why?
| | Genetic Loci | 1 | 2016 | 48 | 0.030 |
Why?
| | Polymers | 1 | 2016 | 51 | 0.030 |
Why?
| | Exercise | 1 | 2020 | 561 | 0.030 |
Why?
| | Public Health Surveillance | 1 | 2016 | 18 | 0.030 |
Why?
| | Age Factors | 2 | 2014 | 1136 | 0.030 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2017 | 181 | 0.030 |
Why?
| | Child Mortality | 1 | 2016 | 12 | 0.030 |
Why?
| | Ethinyl Estradiol | 1 | 2015 | 8 | 0.030 |
Why?
| | Bayes Theorem | 1 | 2016 | 121 | 0.030 |
Why?
| | 9,10-Dimethyl-1,2-benzanthracene | 1 | 2015 | 50 | 0.030 |
Why?
| | Environment | 1 | 2016 | 87 | 0.030 |
Why?
| | Models, Theoretical | 1 | 2016 | 180 | 0.030 |
Why?
| | Health Status Disparities | 1 | 2018 | 221 | 0.030 |
Why?
| | Sp Transcription Factors | 1 | 2014 | 6 | 0.030 |
Why?
| | Pentacyclic Triterpenes | 1 | 2014 | 8 | 0.030 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2015 | 67 | 0.030 |
Why?
| | Cluster Analysis | 1 | 2015 | 238 | 0.030 |
Why?
| | Triterpenes | 1 | 2014 | 11 | 0.030 |
Why?
| | Lysine | 1 | 2015 | 91 | 0.030 |
Why?
| | Neoplasm Transplantation | 1 | 2014 | 86 | 0.030 |
Why?
| | Transplantation, Heterologous | 1 | 2014 | 78 | 0.030 |
Why?
| | Gestational Age | 1 | 2016 | 394 | 0.030 |
Why?
| | Case-Control Studies | 1 | 2018 | 1212 | 0.030 |
Why?
| | Schools | 1 | 2016 | 185 | 0.030 |
Why?
| | Immunity, Innate | 1 | 2015 | 112 | 0.030 |
Why?
| | Mice, Nude | 1 | 2014 | 232 | 0.030 |
Why?
| | Epidemics | 1 | 2014 | 27 | 0.030 |
Why?
| | Sex Distribution | 1 | 2014 | 140 | 0.030 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2014 | 181 | 0.030 |
Why?
| | Stem Cells | 1 | 2015 | 189 | 0.030 |
Why?
| | Genome | 1 | 2014 | 58 | 0.030 |
Why?
| | Epithelial Cells | 1 | 2015 | 218 | 0.030 |
Why?
| | Blotting, Western | 1 | 2014 | 587 | 0.020 |
Why?
| | Cause of Death | 1 | 2014 | 156 | 0.020 |
Why?
| | Acetylation | 1 | 2013 | 97 | 0.020 |
Why?
| | Life Style | 1 | 2014 | 150 | 0.020 |
Why?
| | Models, Statistical | 1 | 2014 | 229 | 0.020 |
Why?
| | Pregnancy Complications, Infectious | 1 | 2014 | 83 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2016 | 1221 | 0.020 |
Why?
| | Infant | 2 | 2012 | 3808 | 0.020 |
Why?
| | Cell Line | 1 | 2015 | 1016 | 0.020 |
Why?
| | Saliva | 1 | 2012 | 56 | 0.020 |
Why?
| | Prevalence | 1 | 2016 | 1034 | 0.020 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2016 | 647 | 0.020 |
Why?
| | Socioeconomic Factors | 1 | 2014 | 623 | 0.020 |
Why?
| | Nerve Tissue Proteins | 1 | 2013 | 193 | 0.020 |
Why?
| | Carrier Proteins | 1 | 2013 | 315 | 0.020 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2018 | 591 | 0.020 |
Why?
| | Incidence | 1 | 2014 | 1085 | 0.020 |
Why?
| | In Situ Hybridization | 1 | 2010 | 69 | 0.020 |
Why?
| | Electrophoretic Mobility Shift Assay | 1 | 2010 | 71 | 0.020 |
Why?
| | Hemochromatosis | 1 | 2009 | 3 | 0.020 |
Why?
| | Antigens, Surface | 1 | 2009 | 37 | 0.020 |
Why?
| | Ohio | 1 | 2009 | 45 | 0.020 |
Why?
| | Manganese | 1 | 2009 | 22 | 0.020 |
Why?
| | Obesity | 1 | 2018 | 1205 | 0.020 |
Why?
| | Statistics as Topic | 1 | 2009 | 89 | 0.020 |
Why?
| | Dihydrotestosterone | 1 | 2007 | 14 | 0.020 |
Why?
| | Time Factors | 1 | 2014 | 2992 | 0.020 |
Why?
| | United States | 1 | 2018 | 5413 | 0.020 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2009 | 505 | 0.020 |
Why?
| | Anticarcinogenic Agents | 1 | 2006 | 32 | 0.020 |
Why?
| | Caspase 3 | 1 | 2006 | 92 | 0.020 |
Why?
| | Down-Regulation | 1 | 2007 | 344 | 0.020 |
Why?
| | RNA, Small Interfering | 1 | 2006 | 214 | 0.010 |
Why?
| | TATA Box | 1 | 2004 | 8 | 0.010 |
Why?
| | Dinucleoside Phosphates | 1 | 2004 | 7 | 0.010 |
Why?
| | DNA Primers | 1 | 2004 | 202 | 0.010 |
Why?
| | Orchiectomy | 1 | 2003 | 38 | 0.010 |
Why?
| | Rats, Inbred Strains | 1 | 2003 | 174 | 0.010 |
Why?
| | Precancerous Conditions | 1 | 2004 | 87 | 0.010 |
Why?
| | Oxidoreductases | 1 | 2003 | 57 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2016 | 6821 | 0.010 |
Why?
| | Neoplasm Metastasis | 1 | 2004 | 237 | 0.010 |
Why?
| | Aldehydes | 1 | 2003 | 81 | 0.010 |
Why?
| | Peptide Elongation Factor 1 | 1 | 2003 | 2 | 0.010 |
Why?
| | Clusterin | 1 | 2003 | 8 | 0.010 |
Why?
| | Amino Acyl-tRNA Synthetases | 1 | 2003 | 7 | 0.010 |
Why?
| | Postoperative Period | 1 | 2003 | 169 | 0.010 |
Why?
| | Cytoskeleton | 1 | 2003 | 39 | 0.010 |
Why?
| | Regeneration | 1 | 2003 | 83 | 0.010 |
Why?
| | Alkaline Phosphatase | 1 | 2003 | 92 | 0.010 |
Why?
| | Molecular Chaperones | 1 | 2003 | 76 | 0.010 |
Why?
| | Glycoproteins | 1 | 2003 | 121 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2009 | 3495 | 0.010 |
Why?
| | Membrane Glycoproteins | 1 | 2003 | 238 | 0.010 |
Why?
| | Neoplasm Staging | 1 | 2004 | 774 | 0.010 |
Why?
|
|
Leung's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|